GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-08

AUTHORS

Jumpei Yoshimura, Kazuma Yamakawa, Takahiro Kinoshita, Yoshinori Ohta, Takeshi Morimoto

ABSTRACT

BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018. More... »

PAGES

614

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2

DOI

http://dx.doi.org/10.1186/s13063-018-2971-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109785241

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30409160


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gentian Violet", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Ventilator-Associated", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sample Size", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshimura", 
        "givenName": "Jumpei", 
        "id": "sg:person.0603331425.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603331425.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamakawa", 
        "givenName": "Kazuma", 
        "id": "sg:person.0662305676.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662305676.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kinoshita", 
        "givenName": "Takahiro", 
        "id": "sg:person.015007222273.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007222273.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohta", 
        "givenName": "Yoshinori", 
        "id": "sg:person.015350567523.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350567523.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13054-017-1747-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086058682", 
          "https://doi.org/10.1186/s13054-017-1747-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-003-1788-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043121337", 
          "https://doi.org/10.1007/s00134-003-1788-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2253-15-19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045178259", 
          "https://doi.org/10.1186/1471-2253-15-19"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-08", 
    "datePublishedReg": "2018-11-08", 
    "description": "BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-018-2971-2", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6834768", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7522581", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "ventilator-associated pneumonia", 
      "initial antibiotic treatment", 
      "intensive care unit", 
      "initial antibiotic therapy", 
      "anti-pseudomonal agents", 
      "broad-spectrum antibiotics", 
      "antibiotic treatment", 
      "pneumonia trials", 
      "antibiotic choice", 
      "antibiotic therapy", 
      "Gram staining", 
      "open-label parallel-group trial", 
      "one-sided alpha level", 
      "common hospital-acquired infection", 
      "resistant Staphylococcus aureus agents", 
      "non-evaluable patients", 
      "clinical response rate", 
      "ICU-free days", 
      "ventilator-free days", 
      "parallel-group trial", 
      "guideline-based treatment", 
      "non-inferiority margin", 
      "selection of antibiotics", 
      "hospital-acquired infections", 
      "anti-MRSA agents", 
      "Medical Information Network", 
      "multidrug-resistant pathogens", 
      "primary endpoint", 
      "secondary endpoints", 
      "cause mortality", 
      "adverse events", 
      "care unit", 
      "endotracheal aspirates", 
      "ICU setting", 
      "guideline group", 
      "study protocol", 
      "patient outcomes", 
      "patients", 
      "response rate", 
      "antibiotic selection strategy", 
      "antibiotic agents", 
      "total sample size", 
      "alpha levels", 
      "trials", 
      "staining", 
      "treatment", 
      "antibiotics", 
      "therapy", 
      "endpoint", 
      "pathogenic bacteria", 
      "agents", 
      "coverage rate", 
      "rapid emergence", 
      "days", 
      "sample size", 
      "multicentre", 
      "pneumonia", 
      "group", 
      "aspirates", 
      "infection", 
      "mortality", 
      "outcomes", 
      "rate", 
      "immediate information", 
      "use", 
      "pathogens", 
      "setting", 
      "rationale", 
      "evidence", 
      "levels", 
      "protocol", 
      "spread", 
      "events", 
      "choice", 
      "bacteria", 
      "combination", 
      "margin", 
      "strategies", 
      "units", 
      "ratio", 
      "results", 
      "challenges", 
      "emergence", 
      "information", 
      "selection", 
      "size", 
      "information networks", 
      "selection strategy", 
      "network", 
      "power"
    ], 
    "name": "GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial", 
    "pagination": "614", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109785241"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2971-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30409160"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2971-2", 
      "https://app.dimensions.ai/details/publication/pub.1109785241"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_768.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-018-2971-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      21 PREDICATES      127 URIs      116 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2971-2 schema:about N1691151e58d748d8a3057b46abef7264
2 N46ef37a271bd4d5bb330dd83b82c70c2
3 N667ed332f6a44e6eaba456aa014894bc
4 N75af860eae5c42a4b09ad42e90b99917
5 N862c31f4d78f4f939573cb01e08ea31f
6 N90fb25bfafe24d22b3a73e753156b57a
7 Nc536a639b5fa4b159ff95775ef5d574c
8 Nf500bab3d06b4056a7c8e341be192408
9 Nf67b4934a3f94f649475c98633a10357
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N97db1bd53b10435080a040c485402d14
13 schema:citation sg:pub.10.1007/s00134-003-1788-x
14 sg:pub.10.1186/1471-2253-15-19
15 sg:pub.10.1186/s13054-017-1747-5
16 schema:datePublished 2018-11-08
17 schema:datePublishedReg 2018-11-08
18 schema:description BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018.
19 schema:genre article
20 schema:isAccessibleForFree true
21 schema:isPartOf N5332f0a4f8c14279b1c878bc7c116617
22 Nc54e9266cca04522b26a6c4f4b523f5f
23 sg:journal.1297400
24 schema:keywords Gram staining
25 ICU setting
26 ICU-free days
27 Medical Information Network
28 adverse events
29 agents
30 alpha levels
31 anti-MRSA agents
32 anti-pseudomonal agents
33 antibiotic agents
34 antibiotic choice
35 antibiotic selection strategy
36 antibiotic therapy
37 antibiotic treatment
38 antibiotics
39 aspirates
40 bacteria
41 broad-spectrum antibiotics
42 care unit
43 cause mortality
44 challenges
45 choice
46 clinical response rate
47 combination
48 common hospital-acquired infection
49 coverage rate
50 days
51 emergence
52 endotracheal aspirates
53 endpoint
54 events
55 evidence
56 group
57 guideline group
58 guideline-based treatment
59 hospital-acquired infections
60 immediate information
61 infection
62 information
63 information networks
64 initial antibiotic therapy
65 initial antibiotic treatment
66 intensive care unit
67 levels
68 margin
69 mortality
70 multicentre
71 multidrug-resistant pathogens
72 network
73 non-evaluable patients
74 non-inferiority margin
75 one-sided alpha level
76 open-label parallel-group trial
77 outcomes
78 parallel-group trial
79 pathogenic bacteria
80 pathogens
81 patient outcomes
82 patients
83 pneumonia
84 pneumonia trials
85 power
86 primary endpoint
87 protocol
88 rapid emergence
89 rate
90 ratio
91 rationale
92 resistant Staphylococcus aureus agents
93 response rate
94 results
95 sample size
96 secondary endpoints
97 selection
98 selection of antibiotics
99 selection strategy
100 setting
101 size
102 spread
103 staining
104 strategies
105 study protocol
106 therapy
107 total sample size
108 treatment
109 trials
110 units
111 use
112 ventilator-associated pneumonia
113 ventilator-free days
114 schema:name GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial
115 schema:pagination 614
116 schema:productId N25862457cb7b415286ecfb232b72e4d7
117 Na282fe4df2564adb84dd5a4d184386eb
118 Nc17d10b7d9584c059618da547641efae
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785241
120 https://doi.org/10.1186/s13063-018-2971-2
121 schema:sdDatePublished 2022-10-01T06:44
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N11acf70d866e46b9b1fff8f5683d0deb
124 schema:url https://doi.org/10.1186/s13063-018-2971-2
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N1190642fe16e4ab5b7d92857be798541 rdf:first sg:person.015007222273.93
129 rdf:rest N7a33617246f842c1bd9fe3c96820edfe
130 N11acf70d866e46b9b1fff8f5683d0deb schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 N1691151e58d748d8a3057b46abef7264 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Randomized Controlled Trials as Topic
134 rdf:type schema:DefinedTerm
135 N25862457cb7b415286ecfb232b72e4d7 schema:name doi
136 schema:value 10.1186/s13063-018-2971-2
137 rdf:type schema:PropertyValue
138 N46ef37a271bd4d5bb330dd83b82c70c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Sample Size
140 rdf:type schema:DefinedTerm
141 N5332f0a4f8c14279b1c878bc7c116617 schema:volumeNumber 19
142 rdf:type schema:PublicationVolume
143 N667ed332f6a44e6eaba456aa014894bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Multicenter Studies as Topic
145 rdf:type schema:DefinedTerm
146 N75af860eae5c42a4b09ad42e90b99917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Anti-Bacterial Agents
148 rdf:type schema:DefinedTerm
149 N7a33617246f842c1bd9fe3c96820edfe rdf:first sg:person.015350567523.38
150 rdf:rest Nc04916ab08fc4117a997e0db2a66ec9d
151 N862c31f4d78f4f939573cb01e08ea31f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Gentian Violet
153 rdf:type schema:DefinedTerm
154 N90fb25bfafe24d22b3a73e753156b57a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Data Interpretation, Statistical
156 rdf:type schema:DefinedTerm
157 N97db1bd53b10435080a040c485402d14 rdf:first sg:person.0603331425.88
158 rdf:rest Nb3fd0efe398a445db8847c5b27b8e781
159 Na282fe4df2564adb84dd5a4d184386eb schema:name dimensions_id
160 schema:value pub.1109785241
161 rdf:type schema:PropertyValue
162 Nb3fd0efe398a445db8847c5b27b8e781 rdf:first sg:person.0662305676.60
163 rdf:rest N1190642fe16e4ab5b7d92857be798541
164 Nc04916ab08fc4117a997e0db2a66ec9d rdf:first sg:person.011273662612.03
165 rdf:rest rdf:nil
166 Nc17d10b7d9584c059618da547641efae schema:name pubmed_id
167 schema:value 30409160
168 rdf:type schema:PropertyValue
169 Nc536a639b5fa4b159ff95775ef5d574c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Phenazines
171 rdf:type schema:DefinedTerm
172 Nc54e9266cca04522b26a6c4f4b523f5f schema:issueNumber 1
173 rdf:type schema:PublicationIssue
174 Nf500bab3d06b4056a7c8e341be192408 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Pneumonia, Ventilator-Associated
176 rdf:type schema:DefinedTerm
177 Nf67b4934a3f94f649475c98633a10357 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Outcome Assessment, Health Care
179 rdf:type schema:DefinedTerm
180 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
181 schema:name Medical and Health Sciences
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
184 schema:name Clinical Sciences
185 rdf:type schema:DefinedTerm
186 sg:grant.6834768 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2971-2
187 rdf:type schema:MonetaryGrant
188 sg:grant.7522581 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2971-2
189 rdf:type schema:MonetaryGrant
190 sg:journal.1297400 schema:issn 1468-6708
191 1745-6215
192 schema:name Trials
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
196 schema:familyName Morimoto
197 schema:givenName Takeshi
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
199 rdf:type schema:Person
200 sg:person.015007222273.93 schema:affiliation grid-institutes:grid.416985.7
201 schema:familyName Kinoshita
202 schema:givenName Takahiro
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007222273.93
204 rdf:type schema:Person
205 sg:person.015350567523.38 schema:affiliation grid-institutes:grid.272264.7
206 schema:familyName Ohta
207 schema:givenName Yoshinori
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350567523.38
209 rdf:type schema:Person
210 sg:person.0603331425.88 schema:affiliation grid-institutes:grid.416985.7
211 schema:familyName Yoshimura
212 schema:givenName Jumpei
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603331425.88
214 rdf:type schema:Person
215 sg:person.0662305676.60 schema:affiliation grid-institutes:grid.416985.7
216 schema:familyName Yamakawa
217 schema:givenName Kazuma
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662305676.60
219 rdf:type schema:Person
220 sg:pub.10.1007/s00134-003-1788-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043121337
221 https://doi.org/10.1007/s00134-003-1788-x
222 rdf:type schema:CreativeWork
223 sg:pub.10.1186/1471-2253-15-19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045178259
224 https://doi.org/10.1186/1471-2253-15-19
225 rdf:type schema:CreativeWork
226 sg:pub.10.1186/s13054-017-1747-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086058682
227 https://doi.org/10.1186/s13054-017-1747-5
228 rdf:type schema:CreativeWork
229 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
230 Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
231 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
232 Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
233 rdf:type schema:Organization
234 grid-institutes:grid.416985.7 schema:alternateName Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan
235 schema:name Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...